KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Safety of niraparib-based regimens in patients with ovarian cancer: A systematic review and meta-analysis. PMID 39908743 · Eur J Obstet Gynecol Reprod Biol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effectiveness of My Tools for Care-in Care: A Pragmatic Randomized Controlled Trial. PMID 39904489 · J Am Med Dir Assoc · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial. PMID 39893343 · Ann Surg Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial. PMID 39892563 · Antiviral Res · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial. PMID 39884302 · Lancet Microbe · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis. PMID 39882926 · Ital J Dermatol Venerol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Standard Versus Reduced Hydration to Improve Elimination of High-Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial. PMID 39868759 · Pediatr Blood Cancer · 2025-Apr Study is an oncology RCT with drug intervention (methotrexate) and original results, but it is a Phase II/pilot study (not Phase III/IIIb), and its primary endpoint is time to drug elimination (pharmacokinetic), not a survival or disease progression time-to-event efficacy endpoint (OS, PFS, DFS, etc.). No Kaplan-Meier curves or hazard ratios are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy for non-spine bone metastases: A meta-analysis and international stereotactic radiosurgery society (ISRS) clinical practice guidelines. PMID 39862925 · Radiother Oncol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Fiber, lactose and fat-modified diet for the prevention of gastrointestinal chemo-radiotherapy-induced toxicity in patients with cervical cancer: Randomized clinical trial. PMID 39848009 · Nutrition · 2025-Apr The study is an oncology RCT with a time-to-event endpoint, but the intervention is dietary (fiber, lactose, fat modification) and not a drug. Phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Meaningful change threshold estimation for the non-small cell lung cancer symptom assessment questionnaire (NSCLC-SAQ): psychometric analysis from a phase 3 trial (LIBRETTO-431). PMID 39847268 · Qual Life Res · 2025-Apr The record describes a psychometric analysis of a patient-reported outcome questionnaire from a Phase 3 randomized trial, but it does not report any primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results, and it does not explicitly specify a drug intervention. Therefore, it does not meet the eligibility criteria for a drug-intervention oncology trial with time-to-event efficacy.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prolonged vs standard thromboprophylaxis in patients with esophageal cancer undergoing surgery: a randomized controlled study. PMID 39842514 · J Thromb Haemost · 2025-Apr While the record is an original randomized controlled trial in oncology with a drug intervention (low-molecular-weight heparin), it does not meet the core requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary endpoint was a biomarker (F1+2), and the secondary outcomes (venous thrombosis incidence, mortality) are not presented as time-to-event analyses with KM or HR. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis. PMID 39841181 · Eur J Clin Pharmacol · 2025-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Aprocitentan for Blood Pressure Reduction in Black Patients. PMID 39840441 · Hypertension · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study. PMID 39828494 · Clin Breast Cancer · 2025-Apr The study is a randomized Phase II trial (ELAINE 1) with a drug intervention, but it reports on secondary patient-reported outcome (vaginal/vulvar symptoms) with descriptive statistics (mean changes in symptom scores), not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia. PMID 39826701 · Am Heart J · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist. PMID 39821928 · Diabetes Obes Metab · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. PMID 39820580 · Diabetologia · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty. PMID 39800203 · Am J Ophthalmol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Accounting for differential exclusions in the Nordic-European initiative on colorectal cancer trial discloses stronger-than-reported effects of screening colonoscopy. PMID 39800010 · J Clin Epidemiol · 2025-Apr The study is a randomized trial in human colorectal cancer (oncology). It is an original report of primary results. However, it evaluates a screening intervention (colonoscopy), not a drug-containing intervention. Furthermore, the primary endpoints are cancer incidence and risk reduction (relative risk, odds ratio), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis with hazard ratio. Phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease. PMID 39798801 · Transplant Cell Ther · 2025-Apr The record describes a non-randomized cohort study evaluating risk stratification and outcomes with a drug-containing chemotherapy regimen, but it lacks evidence of randomization between treatment arms. Eligibility requires a randomized trial, so it is excluded despite other criteria being met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial. PMID 39797697 · BJU Int · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial. PMID 39791315 · Cancer Commun (Lond) · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. PMID 39789843 · Diabetes Obes Metab · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. PMID 39781601 · Diabetes Obes Metab · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recurrence-free survival after hepatectomy using propofol-based total intravenous anaesthesia and sevoflurane-based inhalational anaesthesia: a randomised controlled study. PMID 39776101 · Anaesthesia · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. PMID 39746162 · J Clin Oncol · 2025-Apr The abstract describes a long-term follow-up and biomarker subgroup analysis of the C9741 trial. While it reports overall results (improved DFS and OS for dose-dense chemotherapy), the stated primary purpose and conclusion center on identifying the biomarker-defined subgroup (SET2,3) that benefits, making the report type 'subgroup'. Furthermore, the trial phase is not explicitly stated in the provided metadata (title, abstract, publication types, MeSH), preventing confirmation of the required Phase III/IIIb or Phase II/III criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. PMID 39722400 · J Am Acad Dermatol · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial. PMID 39708985 · Gastroenterology · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. PMID 39707623 · Clin Pharmacol Ther · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial. PMID 39706350 · Gastroenterology · 2025-Apr The study is a randomized, oncology trial reporting a primary result, but it is excluded because the intervention is non-drug (endoscopic screening) and the outcome is not a standard time-to-event efficacy endpoint (e.g., OS, PFS) as defined by the inclusion criteria. No phase information is provided to confirm it is a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. PMID 39700456 · J Clin Oncol · 2025-Apr The study is a Phase III, randomized-controlled trial (RCT) of a drug in oncology, but it is a single-arm trial and the primary endpoint is objective response rate (ORR), not a time-to-event endpoint like OS, PFS, or DFS. The abstract does not report Kaplan-Meier curves or hazard ratios for any time-to-event outcome. Therefore, it does not meet the core requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer. PMID 39694415 · J Thorac Oncol · 2025-Apr This is an original Phase III randomized trial with an oncology focus, but the primary endpoint is time to treatment initiation (TTI), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis of such. Furthermore, the intervention is a diagnostic procedure (liquid biopsy), not a drug-containing intervention. Therefore, it does not meet the eligibility criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial. PMID 39676623 · Ann Neurol · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). PMID 39674398 · Int J Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. PMID 39648559 · Liver Int · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR. PMID 39645016 · J Heart Lung Transplant · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. PMID 39608389 · Lancet Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality. PMID 39601354 · Liver Int · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. PMID 39592058 · J Am Acad Dermatol · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials. PMID 39581330 · Ophthalmology · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Laparoscopic suture-free partial nephrectomy using argon-beam-coagulator: Surgical technique and outcomes of a single-center, open-label randomized controlled trial. PMID 39578201 · Urol Oncol · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer. PMID 39545921 · Mol Oncol · 2025-Apr The record describes a biomarker-focused secondary analysis of the ALICE trial, investigating the prognostic and predictive value of gut microbiota. While it references a randomized trial with a drug intervention and a PFS endpoint, the abstract does not state the trial's phase, and the report's primary focus is not the formal reporting of the trial's primary efficacy results. Therefore, it does not meet the criteria for an original, primary result report of a definitive-phase trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD. PMID 39521398 · Am J Kidney Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study. PMID 39521012 · Lancet Infect Dis · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pragmatic monitoring of emerging efficacy data in randomized controlled trials. PMID 39520228 · Clin Trials · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections. PMID 39447871 · Ophthalmol Retina · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. PMID 39406613 · Eur Urol Oncol · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting. PMID 39394852 · Clin Trials · 2025-Apr The record is a methodological article discussing the design of non-inferiority trials, not an original report of a completed randomized Phase III or II/III clinical trial with drug intervention results. It meets oncology, human, randomized, phase3, and time_to_event signals but is excluded because it is not an original trial result report and lacks a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Redesigning a Stopped Clinical Trial as an Emulated Trial Using Real-World Data to Explore the Effectiveness of Slow-Release Oral Morphine as a Treatment for Opioid Use Disorder. PMID 39394672 · Subst Use Addctn J · 2025-Apr 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial. PMID 39389463 · Ophthalmol Retina · 2025-Apr 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -